Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

157.98 -2.48 (-1.55%)
Official Closing Price Updated: 4:10 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.
These stocks have moved in opposite directions lately, but both could deliver solid returns to patient investors. 
Via The Motley Fool
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy. 
Via The Motley Fool
This Could Be Novo Nordisk's Next Big Weight-Loss Product
The company's sales doubled last quarter, prompting it to upgrade its guidance. 
Via The Motley Fool
The Best Stocks to Invest $5,000 in Right Now
These stocks are showing strong revenue and earnings growth, buoyed by healthcare headwinds. 
Via The Motley Fool
Better Dividend Stock: Eli Lilly or Novo Nordisk?
One of these dividend-paying pharma stocks is a markedly better passive income vehicle. 
Via The Motley Fool
This Pharma's Sales Are So Hot It's Trying to Curb Demand
Wegovy's nearly guaranteed to make Novo Nordisk billions of dollars. 
Via The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
 
Via Benzinga
Why Novo Nordisk Stock Is Falling Today
Investors are worried that Novo's flagship medication may fail to live up to the hype. 
Via The Motley Fool
Novo Nordisk's Oral Weight-Loss Drug Shows Significant Benefit
Novo Nordisk A/S (NYSE: NVO) announced headl 
Via Benzinga
$100 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
InvestorNewsBreaks – Novo Nordisk (NYSE: NVO) Featured in Analysis Report
Via Investor Brand Network
Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected
Like Pfizer and Novo Nordisk, Eli Lilly is also testing an oral GLP-1 in weight loss. 
Via Investor's Business Daily
7 Top Stock Tips for June 2023
The stock market remains unpredictable and volatile. As such, investors should be aware of the following top stock tips for the second half. 
Via InvestorPlace
3 Biotech Stocks With Blockbuster Potential
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics. 
Via InvestorPlace
The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes
Pfizer stock surged on its diabetes news this week, but one analyst says there's a key piece missing from the story. 
Via Investor's Business Daily
Looking At Novo Nordisk's Recent Unusual Options Activity
 
Via Benzinga
Tesla, Zoom, Hepion, Pfizer, ZIM: Why These 5 Stocks Are Drawing Investor Attention Today
 
Via Benzinga
Why Pfizer Stock Crushed the Market on Monday
The pharmaceuctical giant could have a potential blockbuster drug on its hands. 
Via The Motley Fool
S&P 500: Tesla Among Stock Winners Monday; Nike, Micron Slide
Nike and Micron Technology were notable big-cap losers. 
Via Investor's Business Daily
Pfizer Stock Pops: Study Shows Company's Oral Weight Loss Drug Could Be As Effective As Novo Nordic's Ozempic Injection
Pfizer Inc (NYSE: PFE) shares are trading higher Monday in the wake of a newly released study suggesting the company's oral weight loss drug may be as effective as Novo Nordisk's (NYSE: NVO)  
Via Benzinga
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer's diabetes drug led to faster weight loss than Novo Nordisk's Ozempic. 
Via Investor's Business Daily
EU Slaps Meta With Penalty For Data Privacy Violation, Uber's Diversity Leader Faces Heat, China Bans Some Of Micron's Product Sales: Today's Top Stories
Bloomberg 
Via Benzinga
Mayo Clinic Study Highlights Potential of Novo Nordisk's Wegovy for Cardiac Health and Weight Loss
Researchers at the Mayo Clinic found that Novo Nordisk A/S's (NYSE: NVO) Wegovy (semaglutide) reduced the risk of heart disease and boosted weight loss. 
Via Benzinga
If You Invested $10,000 in Novo Nordisk in 2020, This Is How Much You Would Have Today
Is it too late to buy the stock? 
Via The Motley Fool
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth. 
Via MarketBeat
Topics Economy
Exposures Economy
Is Novo Nordisk Stock a Screaming Buy Right Now?
The drugmaker's shares have crushed the broader markets over the past two years. Can it keep up this blistering momentum? 
Via The Motley Fool
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares 
Via MarketBeat
Rebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing
CEOs of Eli Lilly And Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and PBM e 
Via Benzinga
Obesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli Lilly
Boehringer Ingelheim and Zealand Pharma A/S (OTC: ZLDPF) announced that patients treated with BI 456906  
Via Benzinga
How To Trade US CPI: The Top 5 Mega-Cap Gainers And Losers Following Last 3 Inflation Reports
Investors are eagerly awaiting the U.S. inflation statistics for April, which will be announced on Wednesday at 8.30 a.m. ET, before the start of trading on Wall Street. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.